Recent Updates
Recently added Catalysts
EMMA Negative Sentiment

Emmaus Life Sciences Reports Quarterly Financial Results

Key Takeaway: Emmaus Life Sciences reported a decline in financial performance for the third quarter of 2026. The company experienced a 44% drop in U.S. net revenues compared to the same period in 2025. This decline contributed to a decrease in global net revenues, indicating challenges in their market performance.

Market Sentiment Analysis

CONCERNS & RISKS

  • Global net revenues declined compared to the previous year.
  • U.S. net revenues decreased by 44%.

Full Press Release Details

TORRANCE, Calif.--(BUSINESS WIRE)--Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease, today reported on its financial condition and results of operations as of and for the three and nine months ended September 30, 2026. Highlights “Our global net revenues declined for the three months ended September 30, 2026 as compared to the same period in 2025 primarily driven by a 44% decrease in U.S. net revenues as ou

Frequently Asked Questions

What were Emmaus Life Sciences' Q3 revenues?

Emmaus reported a decline in global net revenues for Q3 2026.

How much did U.S. revenues decrease?

U.S. net revenues decreased by 44% compared to Q3 2025.

What is Emmaus Life Sciences known for?

The company is a leader in the treatment of sickle cell disease.

When did Emmaus report its financial results?

Emmaus reported its financial results for the three months ended September 30, 2026.

Last updated: Nov 19, 2026